The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1036
September 25, 1998
View Complete Issue         Table of Contents 2019 
Lepirudin for Heparin-Induced Thrombocytopenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lepirudin for Heparin-Induced Thrombocytopenia
September 25, 1998 (Issue: 1036)
Lepirudin (Refludan - Hoechst Marion Roussel), a direct inhibitor of thrombin, has been approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia and thromboembolic complications.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lepirudin for Heparin-Induced Thrombocytopenia
Article code: 1036b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.